Journal
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
Volume 3, Issue 4, Pages 435-444Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/CER.14.30
Keywords
activities of daily living; multiple sclerosis; quality of life; Sativex (R); spasticity
Categories
Funding
- Almirall
- Biogen
- Genzyme
- Merck
- Novartis
- Sanofi
- Teva
- Laboratorios Almirall S.A.
Ask authors/readers for more resources
In individuals with multiple sclerosis (MS) spasticity, associated symptoms such as spasms, pain, mobility restrictions and sleep disturbances can interfere with the ability to perform activities of daily living and reduce quality of life (QoL). Recent cross-sectional studies from Europe have confirmed that advancing severity of MS spasticity correlates directly with worsening QoL. The treatment effect of Sativex (R) (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain) on QoL has been evaluated in randomized controlled trials, observational studies conducted under everyday clinical practice conditions and a survey in long-term users. Symptomatic relief of MS spasticity in responders to Sativex was associated with quantifiable improvements in QoL and activities of daily living that were maintained over time. Benefits were perceived by both patients and caregivers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available